Featured in this month’s Industry Insight, Dr Anthony Hall speaks to IPT about the importance of R&D into rare conditions, the lack of commercial and scientific interest historically encountered in this area, and the reasons why this situation is now changing.

Read it here:  Q&A: Fundamental Diseases